Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Cost of Care
Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Opening Session Panel Discussion

Advertisement

Advertisement




Dec
04
Today In Oncology
Nivolumab and Ipilimumab in Advanced dMMR/MSI-H Noncolorectal Cancers
FDA Grants Traditional Approval to Pirtobrutinib for CLL/SLL
Lung Cancer Deaths Prevented and Life-Years Gained From Lung Cancer Screening
AYA Cancers Survival for Metastatic Recurrence Worse Than De Novo Metastatic Disease
Survey Finds Global Embrace of Integrative Cancer Care
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo